who else can we blame? , page-17

Cake, great post mate as usual. I think you hold a significant number of shares in Alchemia, to have the levelheadedness you do, can't help but be impressed by this :)

PoS, respect you as a poster (as I love bios and you seem to have a strong understanding of them, having invested in them over a number of years) and can understand why your sentiment has changed but I am disappointed with the calls for Pete's head.

Approval was late but we still got it. The timing and benchmark of the 400k options weren't great but I believe Pete has done a good job in steering ACL to this stage. They successfully navigated through GFC while retaining VAST, HyACT and Fonda and are now in the position of being able to realise value hopefully from all these assets.

When comparing PS with PC from BTA (I hold), the latter's remuneration has increased significantly but they have longer lead times (at least 5 years) to earn substantial revenues, while ACL will do this in a much shorter time period.

ACL has a great pipeline and shortly a reliable revenue stream. If holders can wait another 6 months or more, I am confident the SP will be much higher than what it is now.

Perhaps if Phylogica (I hold) get the other 3 deals this year, they can launch a bid for VAST and that will be a win-win for both :)

I would personally prefer a capital raising than selling rights of Hy-I to fund Phase III as current bidders won't offer much and get a great price for them IMO. I suppose ACL not doing a rights issue supports the theory that larger shareholders are stymying this.

I have shares in UNS (not sure if you were referring to them as a co that didn't do much but then went ballistic in one of your posts on another thread) and the CEO is attacked even though we have a big 4 pharma backing us and he holds a significant portion of the company.

I know the SP of ACL is low, but that IMO is due to negative news on fonda (AG), funding and/or perhaps high expectations (people expected greater take up in US than 10%).

Thanks to great posts on this thread, we know that Reddy's generally take time to get optimal market share.

Most of us long-termers are here for HyACT anyway. Only the day-traders/short-termers IMO are here for fonda, so they will naturally sell if negative news on fonda is released.

If my memory serves me correctly, Alchemia were based in Melbourne but moved up to Qld. Alchemia Oncology is based in Monash (why I and many long-termers are in ACL) so in my mind, they are a Victorian company (Phase II trials conducted at Monash as well). I am biased as I am Victorian, guessing PoS you may be as well :)

Also I think you are forgetting TIS (I hold) when you say Brisbane bios aren't great except for ADO, as they should do very well in the short-term assuming they reach all their targets.